{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:32:03Z","timestamp":1787671923764,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>[\u00b9\u2078F]FDG\u2011PET\/CT is increasingly used to stage invasive bladder cancer (IBC), resulting in growing demand at tertiary centres for time\u2011intensive second\u2011opinion reading of externally acquired scans. However, the incremental clinical value of routine reinterpretation is unclear. We evaluated the clinical impact of second\u2011opinion [\u00b9\u2078F]FDG\u2011PET\/CT reading in a centralised referral network in the Netherlands.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this multicentre retrospective diagnostic cohort study, consecutive patients with histologically confirmed high-grade IBC who underwent externally acquired [\u00b9\u2078F]FDG\u2011PET\/CT followed by expert second\u2011opinion reading at two tertiary centres were evaluated. Initial staging reports were compared with second-opinion staging assessments. Clinically meaningful discrepancies were defined as changes in nodal status (cN0 vs. cN+) or distant metastatic status (cM0 vs. cM1 or cM1a vs. cM1b). Treatment recommendation changes directly attributable to second-opinion reading were recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Six hundred patients were included. Agreement between initial and second\u2011opinion reading was high for both nodal and metastatic staging (\u03ba\u2009=\u20090.89 and \u03ba\u2009=\u20090.87, respectively). Clinically meaningful discrepancies occurred in 33 patients (5.5%), resulting in revised treatment recommendations in 22 patients (3.7%). Suspected nodal disease on the initial report was associated with higher odds of discrepancy at second-opinion reading (OR 2.1, 95% CI 1.0\u20134.4).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this multicentre cohort, routine second\u2011opinion reading of externally acquired [\u00b9\u2078F]FDG\u2011PET\/CT for IBC yielded limited incremental clinical impact within a centralised referral network in the Netherlands. These findings suggest that a more selective approach to second-opinion reading, particularly for patients with suspected nodal disease on the initial report, may warrant further evaluation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-026-08145-1","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T02:19:26Z","timestamp":1787624366000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical impact of routine second\u2011opinion reading of [\u00b9\u2078F]FDG\u2011PET\/CT in newly diagnosed invasive bladder cancer: A multicentre study in a centralised referral network"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4602-979X","authenticated-orcid":false,"given":"Renee A. G.","family":"Lijnen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misha L.","family":"Vierling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanneke B.","family":"Ringia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kees","family":"Hendricksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gijs H.","family":"KleinJan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnoud W.","family":"Postema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter V.","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry N.","family":"Boellaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur J. A. T.","family":"Braat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Heijmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas W. G.","family":"van Rhijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura S.","family":"Mertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"8145_CR1","doi-asserted-by":"publisher","first-page":"833 e9","DOI":"10.1016\/j.urolonc.2021.04.027","volume":"39","author":"M Moussa","year":"2021","unstructured":"Moussa M, Chakra MA, Saad W, Dellis A, Papatsoris A. The role of 18F-FDG PET\/CT scan compared to CT-scan alone for lymph node staging before radical cystectomy in patients with bladder cancer. Urol Oncol. 2021;39:833 e9-e17. https:\/\/doi.org\/10.1016\/j.urolonc.2021.04.027.","journal-title":"Urol Oncol"},{"key":"8145_CR2","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.euo.2021.01.005","volume":"5","author":"CS Voskuilen","year":"2022","unstructured":"Voskuilen CS, van Gennep EJ, Einerhand SMH, Vegt E, Donswijk ML, Bruining A, et al. Staging (18)F-fluorodeoxyglucose Positron Emission Tomography\/Computed Tomography Changes Treatment Recommendation in Invasive Bladder Cancer. Eur Urol Oncol. 2022;5:366\u20139. https:\/\/doi.org\/10.1016\/j.euo.2021.01.005.","journal-title":"Eur Urol Oncol"},{"key":"8145_CR3","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/bju.16091","volume":"132","author":"A Richters","year":"2023","unstructured":"Richters A, van Ginkel N, Meijer RP, Wondergem M, Schoots I, Vis AN, et al. Staging fluorodeoxyglucose positron emission tomography\/computed tomography for muscle-invasive bladder cancer: a nationwide population-based study. BJU Int. 2023;132:420\u20137. https:\/\/doi.org\/10.1111\/bju.16091.","journal-title":"BJU Int"},{"key":"8145_CR4","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.eururo.2022.09.017","volume":"83","author":"LS Mertens","year":"2023","unstructured":"Mertens LS, Meijer RP, Witjes JA. Positron emission tomography\/computed tomography for staging of bladder cancer: a continuing clinical controversy. Eur Urol. 2023;83:95\u20136. https:\/\/doi.org\/10.1016\/j.eururo.2022.09.017.","journal-title":"Eur Urol"},{"key":"8145_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/JU.0000000000003981","volume":"212","author":"J Holzbeierlein","year":"2017","unstructured":"Holzbeierlein J, Bixler BR, Buckley DI, Chang SS, Holmes RS, James AC, et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/SUO guideline (2017; amended 2020, 2024). J Urol. 2017;212:3\u201310. https:\/\/doi.org\/10.1097\/JU.0000000000003981.","journal-title":"J Urol"},{"key":"8145_CR6","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","volume":"87","author":"AG van der Heijden","year":"2025","unstructured":"van der Heijden AG, Bruins HM, Carrion A, Cathomas R, Comperat E, Dimitropoulos K, et al. European Association of Urology Guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 Guidelines. Eur Urol. 2025;87:582\u2013600. https:\/\/doi.org\/10.1016\/j.eururo.2025.02.019.","journal-title":"Eur Urol"},{"key":"8145_CR7","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.euo.2023.10.006","volume":"7","author":"M Baboudjian","year":"2024","unstructured":"Baboudjian M, Grabia A, Barret E, Mathieu R, Rozet F, Lequeu CE, et al. Real-life perioperative outcomes of radical prostatectomy using the French national registry: a plea for promotion of centralized care and access to minimally invasive approaches. Eur Urol Oncol. 2024;7:316\u20138. https:\/\/doi.org\/10.1016\/j.euo.2023.10.006.","journal-title":"Eur Urol Oncol"},{"key":"8145_CR8","doi-asserted-by":"crossref","unstructured":"Naomi J, Fulop AIR, Cecilia Vindrola-Padros CS, Clarke,Rachael Hunter G, Black, Victoria J, Wood M, Melnychuk. Catherine Perry,Laura Vallejo-Torres, Pei Li Ng, Ravi Barod, Axel Bex, Ruth Boaden, Afsana Bhuiya,Veronica Brinton, Patrick Fahy, John Hines, Claire Levermore, Satish Maddineni,Muntzer M Mughal, Kathy Pritchard-Jones, John Sandell, David Shackley,Maxine Tran and Steve Morris. Centralisation of specialist cancer surgery services in two areas of England: the RESPECT\u201321 mixed\u2013methods evaluation. Health and Social Care Delivery Research. London, UK; 2023.","DOI":"10.3310\/QFGT2379"},{"key":"8145_CR9","unstructured":"Rijksoverheid. Integraal Zorg Akkoord \u2013 Samen werken aan gezonde zorg. Den Haag; 2022."},{"key":"8145_CR10","doi-asserted-by":"publisher","first-page":"76","DOI":"10.2340\/sju.v60.43236","volume":"60","author":"A Ullen","year":"2024","unstructured":"Ullen A, Aljabery F, Dahlman P, Falkman K, Gardmark T, Jerlstrom T, et al. Swedish national guidelines on urothelial carcinoma: 2024 update on advanced and metastatic disease. Scand J Urol. 2024;60:76\u201382. https:\/\/doi.org\/10.2340\/sju.v60.43236.","journal-title":"Scand J Urol"},{"key":"8145_CR11","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1245\/s10434-014-4205-5","volume":"22","author":"TL Spivey","year":"2015","unstructured":"Spivey TL, Carlson KA, Janssen I, Witt TR, Jokich P, Madrigrano A. Breast imaging second opinions impact surgical management. Ann Surg Oncol. 2015;22:2359\u201364. https:\/\/doi.org\/10.1245\/s10434-014-4205-5.","journal-title":"Ann Surg Oncol"},{"key":"8145_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.clinimag.2022.03.014","volume":"86","author":"M Virarkar","year":"2022","unstructured":"Virarkar M, Jensen C, Klekers A, Wagner-Bartak NA, Devine CE, Lano EA, et al. Clinical importance of second-opinion interpretations of abdominal imaging studies in a cancer hospital and its impact on patient management. Clin Imaging. 2022;86:13\u20139. https:\/\/doi.org\/10.1016\/j.clinimag.2022.03.014.","journal-title":"Clin Imaging"},{"key":"8145_CR13","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1097\/MNM.0000000000001726","volume":"44","author":"R Fardanesh","year":"2023","unstructured":"Fardanesh R, Beavers K, Jochelson MS, Ulaner GA. Value of subspecialist second opinion reads of 18F-FDG PET-CT examinations for patients with breast cancer. Nucl Med Commun. 2023;44:825\u20139. https:\/\/doi.org\/10.1097\/MNM.0000000000001726.","journal-title":"Nucl Med Commun"},{"key":"8145_CR14","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/MNM.0000000000000647","volume":"38","author":"GA Ulaner","year":"2017","unstructured":"Ulaner GA, Mannelli L, Dunphy M. Value of second-opinion review of outside institution PET-CT examinations. Nucl Med Commun. 2017;38:306\u201311. https:\/\/doi.org\/10.1097\/MNM.0000000000000647.","journal-title":"Nucl Med Commun"},{"key":"8145_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s41824-025-00253-9","volume":"9","author":"F Gutman","year":"2025","unstructured":"Gutman F, Poncin D, Guedec-Ghelfi R, Genin R, David PM, Cuif A, et al. Systematic double reading for oncological PET\/CT scans: insights from a prospective multicentre study in 678 patients. EJNMMI Rep. 2025;9:19. https:\/\/doi.org\/10.1186\/s41824-025-00253-9.","journal-title":"EJNMMI Rep"},{"key":"8145_CR16","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/cpf.12278","volume":"37","author":"J Lofgren","year":"2017","unstructured":"Lofgren J, Loft A, Barbosa de Lima VA, Osterlind K, von Benzon E, Hojgaard L. Clinical importance of re-interpretation of PET\/CT scanning in patients referred to a tertiary care medical centre. Clin Physiol Funct Imaging. 2017;37:143\u20137. https:\/\/doi.org\/10.1111\/cpf.12278.","journal-title":"Clin Physiol Funct Imaging"},{"key":"8145_CR17","unstructured":"Brierley JD, Giuliani M, O\u2019Sullivan B, Rous B, Eycken EV. Urological Tumours. In: TNM Classification of Malignant Tumours. 9th ed. Hoboken: Wiley; 2025. p. 183\u2013202."},{"key":"8145_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2024.111873","volume":"183","author":"GJR Cook","year":"2025","unstructured":"Cook GJR, Alberts IL, Wagner T, Fischer BM, Nazir MS, Lilburn D. The impact of long axial field of view (LAFOV) PET on oncologic imaging. Eur J Radiol. 2025;183:111873. https:\/\/doi.org\/10.1016\/j.ejrad.2024.111873.","journal-title":"Eur J Radiol"},{"key":"8145_CR19","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41568-023-00576-4","volume":"23","author":"J Schwenck","year":"2023","unstructured":"Schwenck J, Sonanini D, Cotton JM, Rammensee HG, la Fougere C, Zender L, et al. Advances in PET imaging of cancer. Nat Rev Cancer. 2023;23:474\u201390. https:\/\/doi.org\/10.1038\/s41568-023-00576-4.","journal-title":"Nat Rev Cancer"},{"key":"8145_CR20","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med. 2024;390:875\u201388. https:\/\/doi.org\/10.1056\/NEJMoa2312117.","journal-title":"N Engl J Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08145-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08145-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08145-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:07:23Z","timestamp":1787670443000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-08145-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":20,"alternative-id":["8145"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08145-1","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"assertion":[{"value":"6 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the institutional review board of The Netherlands Cancer Institute (IRBd25\u2011199).","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for informed consent was waived by the Institutional Review Board. In accordance with institutional policy, only data from patients who had not objected to the use of their clinical data for research were included.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images in Fig.\u00a02.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Author Arthur J.A.T. Braat serves as a consultant for Boston Scientific, GE Healthcare and Telix Pharmaceuticals, and has received research support from Boston Scientific, GE Healthcare, Telix Pharmaceuticals, Ariceum Therapeutics and Siemens Healthineers.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}